GlobeNewswire: KalVista Pharmaceuticals, Inc. Contains the last 10 of 9 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T08:27:01ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/08/08/1081504/0/en/KalVista-Pharmaceuticals-to-Present-at-Wedbush-PacGrow-Healthcare-Conference.html?f=22&fvtc=4&fvtv=29005KalVista Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference2017-08-08T11:30:00Z<![CDATA[CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, Aug. 08, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017, at 3:05 p.m. EDT in New York City.]]>https://www.globenewswire.com/news-release/2017/07/27/1063695/0/en/KalVista-Pharmaceuticals-Provides-Operational-Update-and-Reports-Fiscal-Fourth-Quarter-and-Full-Year-Financial-Results.html?f=22&fvtc=4&fvtv=29005KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Fourth Quarter and Full Year Financial Results2017-07-27T20:01:00Z<![CDATA[– Oral Plasma Kallikrein Inhibitor Portfolio for Treatment of Hereditary Angioedema Continues to Advance –]]>https://www.globenewswire.com/news-release/2017/06/01/1005259/0/en/KalVista-Pharmaceuticals-to-Present-at-Jefferies-Healthcare-Conference.html?f=22&fvtc=4&fvtv=29005KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference2017-06-01T11:30:00Z<![CDATA[CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, June 01, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the Jefferies Healthcare Conference on Thursday, June 8, 2017, at 9:30 a.m. EDT in New York City.]]>https://www.globenewswire.com/news-release/2017/05/15/984780/0/en/KalVista-Pharmaceuticals-to-Recognize-HAE-Day-2017.html?f=22&fvtc=4&fvtv=29005KalVista Pharmaceuticals to Recognize HAE Day 20172017-05-15T11:30:00Z<![CDATA[– Continuing to Develop a Portfolio of Oral Plasma Kallikrein Inhibitors for Treatment of Hereditary Angioedema and Diabetic Macular Edema – – Continuing to Develop a Portfolio of Oral Plasma Kallikrein Inhibitors for Treatment of Hereditary Angioedema and Diabetic Macular Edema –]]>https://www.globenewswire.com/news-release/2017/03/16/940410/0/en/KalVista-Pharmaceuticals-Reports-Fiscal-Third-Quarter-Results.html?f=22&fvtc=4&fvtv=29005KalVista Pharmaceuticals Reports Fiscal Third Quarter Results2017-03-16T20:15:00Z<![CDATA[–  Continuing to Develop a Portfolio of Oral Plasma Kallikrein Inhibitors for HAE –– Intravitreal DME Program Remains on Track for Phase 2 in 2017 –– Company Expects to be Well-Funded Through Data Inflection Points –]]>https://www.globenewswire.com/news-release/2017/03/09/933841/0/en/KalVista-Pharmaceuticals-Appoints-Dr-Andreas-Maetzel-Senior-Vice-President-of-Medical.html?f=22&fvtc=4&fvtv=29005KalVista Pharmaceuticals Appoints Dr. Andreas Maetzel Senior Vice President of Medical2017-03-09T12:30:00Z<![CDATA[Executive Brings Strong Medical and Regulatory Affairs Background and Deep HAE Expertise Executive Brings Strong Medical and Regulatory Affairs Background and Deep HAE Expertise]]>https://www.globenewswire.com/news-release/2016/11/29/893395/0/en/KalVista-Pharmaceuticals-Appoints-Edward-P-Feener-Ph-D-as-Chief-Scientific-Officer.html?f=22&fvtc=4&fvtv=29005KalVista Pharmaceuticals Appoints Edward P. Feener, Ph.D. as Chief Scientific Officer2016-11-29T12:30:00Z<![CDATA[Leading Plasma Kallikrein Researcher Further Strengthens Scientific Team Leading Plasma Kallikrein Researcher Further Strengthens Scientific Team]]>https://www.globenewswire.com/news-release/2016/11/22/892006/0/en/KalVista-Pharmaceuticals-Announces-Closing-of-Merger-with-Carbylan-Therapeutics.html?f=22&fvtc=4&fvtv=29005KalVista Pharmaceuticals Announces Closing of Merger with Carbylan Therapeutics2016-11-22T12:30:00Z<![CDATA[—Combined company renamed KalVista Pharmaceuticals, Inc., listed on Nasdaq with ticker “KALV” —]]>https://www.globenewswire.com/news-release/2016/06/22/850703/0/en/Carbylan-Therapeutics-and-KalVista-Pharmaceuticals-Conference-Call-to-Discuss-Proposed-Transaction.html?f=22&fvtc=4&fvtv=29005Carbylan Therapeutics and KalVista Pharmaceuticals Conference Call to Discuss Proposed Transaction2016-06-22T20:00:00Z<![CDATA[Companies to Host Conference Call Friday, June 24th at 8:00am ET Companies to Host Conference Call Friday, June 24th at 8:00am ET]]>